The 6 most recent market catalysts affecting $HOWL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 92
Werewolf Therapeutics shares are trading higher after the company announced a merger with Ambros Therapeutics. The companies secured commitments for an oversubscribed concurrent private placement of $150 million from a syndicate of leading healthcare-dedicated investor.
The merger between Werewolf Therapeutics and Ambros Therapeutics, coupled with a $150 million oversubscribed private placement, is a major positive catalyst for both companies. Thi…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 85
Werewolf Therapeutics Announces All-Stock Merger With Ambros Therapeutics At Implied Values Of $500M For Ambros, $47.5M For Werewolf; Concurrent $150M Private Placement, Werewolf Holders To Own About 6.8%
This merger represents a significant corporate catalyst for both Werewolf Therapeutics and Ambros Therapeutics. Werewolf shareholders face substantial dilution, owning only about 6…
Aug 21, 2026
Corporate Catalyst
Bullish
Impact 95
Werewolf Therapeutics (HOWL) Stock Is Trending Overnight—Here's Why It Jumped 90% After Hours
Werewolf Therapeutics (HOWL) announced the sale of its pre-clinical INDUCER and INDUKINE technology platforms to EMD Serono, a subsidiary of Merck KGaA, for a total of $33 million …
Aug 20, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Thursday's After-Market Session
This 8-K filing highlights the volatility in the healthcare sector during after-market trading, with several companies experiencing notable price changes. The movements are attribu…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 85
Werewolf Therapeutics shares are trading higher after the company announced the sale of its pre-clinical INDUCER platform and its INDUKINE platform to EMD Serono Research & Development Institute.
The sale of its INDUCER and INDUKINE platforms is a major corporate catalyst for Werewolf Therapeutics. This transaction provides immediate capital, which can be used to fund ongoi…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 92
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M
Werewolf Therapeutics reported Q2 earnings of $0.08 per share, dramatically beating the analyst consensus estimate of $(0.29) by 127.59%. This marks a significant improvement from …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.